• Subscribe
  • Webinars
  • White Papers
  • Buyer's Guide
  • PhotonicsNXT
  • Get Published!
    • Recent Quotes
    My Watchlist
    Indicators
    BioOptics Stock Watch
    Markets
    Stocks
    ETFs
    Tools
    Markets:
    Overview
    News
    Currencies
    International
    Treasuries

    Prothena Corporation plc - Ordinary Shares (NQ:PRTA)

    9.240 +0.190 (+2.10%)
    Streaming Delayed Price Updated: 9:58 AM EST, Jan 9, 2026 Add to My Watchlist
    Quote
    Overview Detailed Quote Charting Historical Prices
    News
    All News News Headlines Press Releases
    Research
    Quarterly Reports Insider Filings Other Filings

    Price and Volume

    Detailed Quote
    Volume 41,021
    Open 9.190
    Bid (Size) 9.230 (200)
    Ask (Size) 9.310 (100)
    Prev. Close 9.050
    Today's Range 9.125 - 9.280
    52wk Range 4.320 - 16.66
    Shares Outstanding 45,047,449
    Dividend Yield N/A
    Chart for (: )
    Intraday 1 Week 1 Month 3 Month 1 Year 3 Year 5 Year

    Top News

    More News
    News headline image
    Prothena Announces Board of Directors Update
    From Prothena Corporation plc
    Via Business Wire
    News headline image
    Prothena Announces Poster Presentation on its TDP-43 CYTOPE® Program at Neuroscience 2025
    From Prothena Corporation plc
    Via Business Wire

    Performance

    YTD
    +0.4%
    +0.4%
    1 Month
    -10.5%
    -10.5%
    3 Month
    -10.3%
    -10.3%
    6 Month
    +40.6%
    +40.6%
    1 Year
    -34.7%
    -34.7%

    More News

    Read More
    News headline image
    Novo Nordisk's $100 Million Coramitug Shows Promise In Reducing Heart Failure Biomarker ↗
    Via Benzinga
    News headline image
    Earnings Scheduled For November 6, 2025 ↗
    Via Benzinga
    News headline image
    9 Analysts Assess Prothena Corp: What You Need To Know ↗
    Via Benzinga
    News headline image
    Earnings Scheduled For August 4, 2025 ↗
    Via Benzinga
    News headline image
    A Glimpse of Prothena Corp's Earnings Potential ↗
    Via Benzinga
    News headline image
    Prothena Highlights Phase 2 Data for Coramitug (Formerly PRX004) Published in Circulation, Official Journal of AHA
    From Prothena Corporation plc
    Via Business Wire
    News headline image
    Prothena Corp PLC (NASDAQ:PRTA) Reports Q3 2025 Earnings and Key Pipeline Milestones ↗
    Via Chartmill
    News headline image
    Prothena Reports Third Quarter 2025 Financial Results and Business Highlights
    From Prothena Corporation plc
    Via Business Wire
    News headline image
    Prothena to Report Third Quarter 2025 Financial Results on November 6
    From Prothena Corporation plc
    Via Business Wire
    News headline image
    Deep Dive Into Prothena Corp Stock: Analyst Perspectives (7 Ratings) ↗
    Via Benzinga
    News headline image
    Prothena’s Partner Bristol Myers Squibb Obtains Fast Track Designation from the U.S. FDA for BMS-986446 (PRX005), an Anti-MTBR-Tau-Targeting Antibody, for the Treatment of Alzheimer’s Disease
    From Prothena Corporation plc
    Via Business Wire
    News headline image
    Alibaba To Rally More Than 12%? Here Are 10 Top Analyst Forecasts For Tuesday ↗
    Via Benzinga
    News headline image
    FDA Tightens Safety Guidelines For Biogen Leqembi Alzheimer's Therapy ↗
    Via Benzinga
    News headline image
    Prothena to Participate in the Cantor Fitzgerald Global Healthcare Conference
    From Prothena Corporation plc
    Via Business Wire
    News headline image
    Prothena Reports Non-Competitive Brain Swelling Rates In Early Alzheimer's Study ↗
    Via Benzinga
    News headline image
    What 4 Analyst Ratings Have To Say About Prothena Corp ↗
    Via Benzinga
    News headline image
    Prothena Provides Update on PRX012 and Announces Results from the Phase 1 ASCENT Clinical Program
    From Prothena Corporation plc
    Via Business Wire
    News headline image
    Novo Nordisk Commits To Advancing Prothena Corp-Developed Drug Into Late Stage Trial: Retail Turns Hopeful ↗
    Via Stocktwits
    Topics Earnings
    News headline image
    Prothena Announces that Novo Nordisk Will Advance Coramitug (Formerly PRX004) into Phase 3 Development for ATTR Amyloidosis with Cardiomyopathy
    From Prothena Corporation plc
    Via Business Wire
    News headline image
    Prothena Q2 Revenue Drops 97% ↗
    Via The Motley Fool
    Topics Intellectual Property
    News headline image
    Prothena Reports Second Quarter 2025 Financial Results and Business Highlights
    From Prothena Corporation plc
    Via Business Wire
    News headline image
    Prothena to Report Second Quarter 2025 Financial Results on August 4
    From Prothena Corporation plc
    Via Business Wire
    News headline image
    8 Analysts Assess Prothena Corp: What You Need To Know ↗
    Via Benzinga

    Frequently Asked Questions

    Is Prothena Corporation plc - Ordinary Shares publicly traded?
    Yes, Prothena Corporation plc - Ordinary Shares is publicly traded.
    What exchange does Prothena Corporation plc - Ordinary Shares trade on?
    Prothena Corporation plc - Ordinary Shares trades on the Nasdaq Stock Market
    What is the ticker symbol for Prothena Corporation plc - Ordinary Shares?
    The ticker symbol for Prothena Corporation plc - Ordinary Shares is PRTA on the Nasdaq Stock Market
    What is the current price of Prothena Corporation plc - Ordinary Shares?
    The current price of Prothena Corporation plc - Ordinary Shares is 9.240
    When was Prothena Corporation plc - Ordinary Shares last traded?
    The last trade of Prothena Corporation plc - Ordinary Shares was at 01/09/26 09:58 AM ET
    What is the market capitalization of Prothena Corporation plc - Ordinary Shares?
    The market capitalization of Prothena Corporation plc - Ordinary Shares is 416.24M
    How many shares of Prothena Corporation plc - Ordinary Shares are outstanding?
    Prothena Corporation plc - Ordinary Shares has 416M shares outstanding.
    Stock Quote API & Stock News API supplied by www.cloudquote.io
    Quotes delayed at least 20 minutes.
    By accessing this page, you agree to the Privacy Policy and Terms Of Service.
    © 2025 FinancialContent. All rights reserved.